Reaction
Bile Duct Cancer reporting signals
As of the last recalculation, Bile Duct Cancer appears in 1,180 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 14.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 30 | 14.0 | 14.1 |
| Durvalumab | 14 | 12.3 | 12.3 |
| Bicalutamide | 9 | 10.5 | 10.5 |
| Pitavastatin Calcium | 5 | 8.7 | 8.7 |
| Ranitidine Hydrochloride | 26 | 8.6 | 8.6 |
| Sevoflurane | 4 | 8.5 | 8.5 |
| Gemcitabine Hydrochloride | 23 | 7.8 | 7.8 |
| Gemcitabine | 17 | 7.7 | 7.7 |
| Exenatide | 20 | 6.8 | 6.8 |
| Romosozumab-Aqqg | 5 | 6.5 | 6.5 |
| Romiplostim | 5 | 5.9 | 5.9 |
| Ledipasvir And Sofosbuvir | 6 | 5.5 | 5.5 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 4.8 | 4.8 |